H. David

发表

Phase I pilot study of the safety and tolerability of olanzapine (OZA) for the treatment of cachexia in patients with advanced cancer

E. Bruera, R. Kurzrock, F. Braiteh, 2008 .

Phase I study of low-dose hypomethylating agent azacitidine (5-AC) combined with the histone deacetylase inhibitor valproic acid (VPA) in patients with advanced cancers.

C. Ng, R. Kurzrock, G. Garcia-Manero, 2006, Journal of Clinical Oncology.